IVON Trial

Intravenous versus oral iron for iron deficiency anaemia in pregnant Nigerian women

896

Women Randomized

448

FCM Group (Ferrous Carboxymaltose)

448

FS Group (Ferrous Sulphate)

as at Tuesday, 4th October, 2022.

About IVON

Anaemia in pregnancy (AIP) remains a critical global health problem especially in low- and middle-income countries (LMICs), affecting 46% of pregnant women in Africa and 49% in Asia. Iron deficiency anaemia (IDA) is the commonest cause of AIP, accounting for 50-75% of AIP.

Our aim is to compare the effectiveness of intravenous ferric carboxymaltose (intervention) versus oral ferrous sulphate (control) for treating anaemia and IDA in pregnancy and to measure the acceptability, feasibility, fidelity (implementation outcomes) and the cost-effectiveness of intravenous iron among pregnant Nigerian women with moderate and severe anaemia, and IDA at 20–32 weeks’ gestation.

IVON Trial Overview

Play Video

Sponsor:

Funded By: